NASDAQ:QCLS

Mymd Pharmaceuticals Q3 2026 Earnings Results & Report

Mymd Pharmaceuticals logo
$0.31 -0.03 (-8.29%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$0.31 0.00 (-0.10%)
As of 11/18/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mymd Pharmaceuticals reported Q3 2026 earnings on November 16, 2026. The company reported EPS of -$0.14.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
7:00 AM ET

Mymd Pharmaceuticals EPS Results

Actual EPS
-$0.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Mymd Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Mymd Pharmaceuticals Q3 2026 Earnings FAQ

Mymd Pharmaceuticals (NASDAQ:QCLS) reported earnings of -$0.14 per share for Q3 2026. The report was announced on Monday, November 16, 2026.

Mymd Pharmaceuticals Earnings Headlines

Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
See More Mymd Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mymd Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mymd Pharmaceuticals and other key companies, straight to your email.

About Mymd Pharmaceuticals

Mymd Pharmaceuticals (NASDAQ:QCLS) is a clinical-stage biopharmaceutical company that has focused on developing treatments for inflammatory and age-related conditions. Its work has centered on drug candidates intended to address diseases for which existing treatment options may be limited.

The company’s lead candidate, MYMD-1, is an investigational oral therapy designed to regulate inflammatory processes and the immune system. MyMD has studied its potential application across a range of chronic conditions; it is not an approved medicine.

MyMD has also advanced Supera-CBD, a synthetic cannabinoid candidate investigated for potential therapeutic uses. The company’s activities have been focused on drug research and development rather than marketing an established portfolio of commercial medicines.

View Mymd Pharmaceuticals Profile